Applies to Employer and ACA Marketplace plans.
Covered with requirementsQualification pathways
You can qualify through any one of these.
Type 2 Diabetes Mellitus – age-based approval (injection and tablets)
All of:
- Diagnosis of type 2 diabetes mellitus
- Patient is ≥ 18 years of age
Documentation to bring
- Documentation of type 2 diabetes mellitus diagnosis
- Patient age ≥ 18 years
Approval and renewal
- Initial approval: 12 months
Not covered when
- Weight loss without type 2 diabetes diagnosis
- Prediabetes/diabetes prevention
- Metabolic syndrome without type 2 diabetes
- Concomitant use with other GLP-1 agonists or GLP-1/GIP agonists
- Type 1 diabetes
Policy note: Covers both Ozempic subcutaneous injection and Ozempic tablets (semaglutide tablets; formerly Rybelsus 1.5 mg, 4 mg, 9 mg rebranded as of January 30, 2026). Automation exists for Ozempic tablets added effective 05/06/2026. Policy also notes Ozempic has labeled CV risk reduction and CKD indications but this policy only addresses the diabetes indication; those indications are not separately covered under this diabetes-specific PA policy.
Policy effective May 6, 2026 · verified June 2, 2026 · source: Cigna — GLP-1 coverage criteria (Policy 360) · View policy document (PDF)